Loading clinical trials...
Loading clinical trials...
A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed Protocol EMR-700461-023 (ADDRESS II)
Conditions
Interventions
Atacicept 75 mg
Atacicept 150 mg
+1 more
Locations
84
United States
Pinnacle Research Group LLC
Anniston, Alabama, United States
University of Alabama at Birmingham - (UAB)
Birmingham, Alabama, United States
Wallace Rheumatic Study Center
Beverly Hills, California, United States
Southern California Permenent Medical Group
Fontana, California, United States
East Bay Rheumatology Medical Group, Inc.
San Leandro, California, United States
Clinical Research of West Florida - Corporate
Clearwater, Florida, United States
Start Date
July 29, 2014
Primary Completion Date
April 5, 2016
Completion Date
February 9, 2018
Last Updated
March 21, 2019
NCT07330245
NCT07015983
NCT07438496
NCT06673043
NCT05648500
NCT06881290
Lead Sponsor
EMD Serono
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions